allogeneic rituximab conjugated gamma delta T cells ACE1831

An off-the-shelf preparation of a subset of allogeneic T lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) conjugated to a DNA linker, attached via DNA hybridization to rituximab conjugated to another DNA linker, with potential immunomodulating and antineoplastic activities. Upon administration of the allogeneic rituximab conjugated gamma delta T cells ACE1831, rituximab targets and binds to CD20 expressed on tumor cells. The gamma delta T cells secrete interferon-gamma (IFN-g) and exert direct killing of the CD20-expressing tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor cells. Gamma delta T lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.